Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Artemis Health, Inc. (Artemis Health) has appointed Richard Rava as senior vice president (SVP) of research and development of the company. In this newly created position, Rava brings over 20 years of research, development and operational expertise in molecular and genetic analysis for commercial assays and instrumentation. He joins Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of research and development.
Subscribe to our email newsletter
During his period, Rava led the research, development and manufacturing scale-up of the Affymetrix’ GeneChip technology. He was incharge for the delivery of multiple products involving complex assays, microarrays, instrumentation and software that applied scientific technology to meet the needs of the gene expression, genetics research and clinical markets. before to co-founding Affymetrix, Rava served as a senior scientist at Affymax Research Institute. From 1990 through 1992, he served as principal research scientist at the George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology (MIT). During that time, he was also the research coordinator for the National Institute of Health Laser Biomedical Research Center at MIT. Rava has published over 60 papers in peer-reviewed scientific publications and is an author on over 30 issued US patents. He received his B.A. and Ph.D., in chemistry from Rutgers University.
“Rich’s depth and breadth of research, development and manufacturing experience, together with his proven track record in commercializing genetic analysis tools, makes him uniquely suited to lead our efforts to bring non-invasive prenatal diagnostic tests to the market,” said Lissa Goldenstein, president and chief executive officer of Artemis Health.
“Artemis Health is the only company focused exclusively on the development of non-invasive prenatal tests to determine genetic abnormalities using both intact cell and cell-free fetal DNA analysis tools,” remarked Dr. Rava. “I am extremely excited to join this highly-committed team, and look forward to playing an active role in the rapidly evolving field of prenatal diagnostics.”